Coherus Oncology, Inc.
corporate_fare Company Profile
Coherus Oncology, Inc. (NASDAQ:CHRS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for CHRS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for CHRS spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- Coherus 10-Q: Going-Concern Doubt With $83.6M Cash After $14.3M Q3 Revenue
- Coherus Q3 Revenue Misses; Cuts ~30% of Staff, Narrows Pipeline to Esophageal Cancer
- Coherus Q3 Revenue Misses at $14.3M, Net Loss Widens to $39.3M
- Coherus Tagmokitug Hits 75% ORR in Front-Line Esophageal Cancer
- Coherus Hires Oppenheimer to Sell Legacy Biosimilar Assets
Financial Snapshot
Short Interest & Short Volume
8.20 days to coverFINRA reported short interest of 12,712,857 shares in CHRS as of the October 30, 2026 settlement, a 2.1% increase from the prior period — about 8.2 days to cover at its recent average daily volume. On November 19, 2026, 61.0% of CHRS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for CHRS, detected from its recent SEC filings · based on capital-structure filings through 2026-08-28.
New $50M ATM Program Established · Replaces Terminated $64.9M ATM
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →